Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
340 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atopic Dermatitis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Atopic Dermatitis - Pipeline Review, H2 2015', provides an overview of the Atopic Dermatitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Atopic Dermatitis Overview 11 Therapeutics Development 12 Pipeline Products for Atopic Dermatitis - Overview 12 Pipeline Products for Atopic Dermatitis - Comparative Analysis 13 Atopic Dermatitis - Therapeutics under Development by Companies 14 Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 21 Atopic Dermatitis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Atopic Dermatitis - Products under Development by Companies 26 Atopic Dermatitis - Products under Investigation by Universities/Institutes 33 Atopic Dermatitis - Companies Involved in Therapeutics Development 34 Abeome Corporation 34 AlbireoPharma 35 Almirall, S.A. 36 Amgen Inc. 37 Amorepacific Corporation 38 Anacor Pharmaceuticals, Inc. 39 AnaMar AB 40 AnaptysBio, Inc. 41 AnGes MG, Inc. 42 Aquinox Pharmaceuticals Inc. 43 arGEN-X BV 44 Blueberry Therapeutics Ltd 45 Brickell Biotech, Inc. 46 Celgene Corporation 47 ChemoCentryx, Inc. 48 ChironWells GmbH 49 Chugai Pharmaceutical Co., Ltd. 50 Creabilis SA 51 Delenex Therapeutics AG 52 Dermira Inc. 53 Dr. August Wolff GmbH & Co. KG Arzneimittle 54 Eisai Co., Ltd. 55 F. Hoffmann-La Roche Ltd. 56 Foamix Pharmaceuticals Ltd. 57 Fountain Biopharma Inc. 58 GlaxoSmithKline Plc 59 Glenmark Pharmaceuticals Ltd. 60 Grupo Ferrer Internacional, S.A. 61 Han Wha Pharma Co., Ltd. 62 HanAll Biopharma Co., Ltd. 63 Herantis Pharma Plc 64 iCo Therapeutics Inc. 65 IMMD Inc. 66 Immune Pharmaceuticals Inc. 67 Inflamalps SA 68 Japan Tobacco Inc. 69 Johnson & Johnson 70 LegoChem Biosciences, Inc 71 LEO Pharma A/S 72 Madam Therapeutics B.V. 73 MedImmune, LLC 74 Mitsubishi Tanabe Pharma Corporation 75 NeoPharm Co., Ltd. 76 Novartis AG 77 Nuvo Research Inc. 78 Otsuka Holdings Co., Ltd. 79 Oxagen Limited 80 Pfizer Inc. 81 Pharis Biotec GmbH 82 Pharmedartis GmbH 83 Provectus Biopharmaceuticals, Inc. 84 R-Tech Ueno, Ltd. 85 Regeneron Pharmaceuticals, Inc. 86 Signum Dermalogix, Inc 87 Spherium Biomed S.L. 88 sterna biologicals Gmbh & Co KG 89 Sun Pharma Advanced Research Company Ltd. 90 SWITCH Biotech LLC 91 Takeda Pharmaceutical Company Limited 92 Thesan Pharmaceuticals, Inc. 93 Valeant Pharmaceuticals International, Inc. 94 Vicore Pharma AB 95 Vitae Pharmaceuticals, Inc. 96 VivaCell Biotechnology Espana S.L. 97 Welichem Biotech Inc. 98 Xencor, Inc. 99 Yungjin Pharm. Co., Ltd. 100 Ziarco Pharma Ltd 101 Atopic Dermatitis - Therapeutics Assessment 102 Assessment by Monotherapy Products 102 Assessment by Target 103 Assessment by Mechanism of Action 107 Assessment by Route of Administration 110 Assessment by Molecule Type 112 Drug Profiles 114 A-3914 - Drug Profile 114 A-5425 - Drug Profile 115 AKP-11 - Drug Profile 116 ALX-101 - Drug Profile 118 AM-1030 - Drug Profile 119 AN-2898 - Drug Profile 120 AN-4161 - Drug Profile 121 ANB-020 - Drug Profile 122 apremilast - Drug Profile 123 Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 126 AQX-1125 - Drug Profile 127 ARGX-112 - Drug Profile 129 ARN-077 - Drug Profile 130 BB-2702 - Drug Profile 131 BBI-2111 - Drug Profile 132 BBI-5000 - Drug Profile 133 bertilimumab - Drug Profile 134 Biologic for Atopic Dermatitis and Eczema - Drug Profile 136 BPR-277 - Drug Profile 137 C-21 - Drug Profile 138 CBP-174 - Drug Profile 140 CBP-201 - Drug Profile 141 CCX-6239 - Drug Profile 142 CDE-001 - Drug Profile 143 Cis-Urocanic Acid - Drug Profile 144 CNTO-7160 - Drug Profile 147 cobamamide - Drug Profile 148 crisaborole - Drug Profile 149 CT-1x1 - Drug Profile 151 CT-1x2 - Drug Profile 152 CT-1x3 - Drug Profile 153 CT-327 - Drug Profile 154 CT-340 - Drug Profile 156 cyclosporine - Drug Profile 157 DRM-02 - Drug Profile 158 Drug for Atopic Dermatitis - Drug Profile 159 Drugs to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 160 dupilumab - Drug Profile 161 E-6005 - Drug Profile 164 FB-825 - Drug Profile 165 fevipiprant - Drug Profile 166 FIB-116 - Drug Profile 168 Furestem-AD - Drug Profile 169 GBR-830 - Drug Profile 170 Histimex - Drug Profile 171 HS-378 - Drug Profile 172 IMD-0354 - Drug Profile 173 JTE-052 - Drug Profile 174 KTG-001 - Drug Profile 175 LCB-030110 - Drug Profile 176 lebrikizumab - Drug Profile 177 LEKTI-6 - Drug Profile 179 LEO-32731 - Drug Profile 180 LEO-39652 - Drug Profile 181 mepolizumab - Drug Profile 182 MLR-1130 - Drug Profile 185 mometasone furoate - Drug Profile 186 Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile 187 Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 188 N-oleoylethanolamine - Drug Profile 189 nemolizumab - Drug Profile 190 NPB-3 - Drug Profile 191 NPH-12 - Drug Profile 192 OC-000459 - Drug Profile 193 OC-2417 - Drug Profile 195 octenidine hydrochloride - Drug Profile 196 OLX-103 - Drug Profile 197 omiganan pentahydrochloride - Drug Profile 198 OPA-15406 - Drug Profile 200 P-10 - Drug Profile 201 PAC-14028 - Drug Profile 202 PDI-192 - Drug Profile 204 Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 205 Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 206 PH-10 - Drug Profile 207 PL-601 - Drug Profile 209 PMA-101R - Drug Profile 210 PMA-201 - Drug Profile 211 PMA-411R - Drug Profile 212 Q-301 - Drug Profile 213 Qi-507 - Drug Profile 214 roflumilast - Drug Profile 215 RTU-1096 - Drug Profile 218 S-414114 - Drug Profile 219 SB-011 - Drug Profile 221 SIG-1311 - Drug Profile 222 SIG-1322 - Drug Profile 223 Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 224 Small Molecules for Atopic Dermatitis - Drug Profile 225 Small Molecules to Inhibit Kinase for Inflammatory Diseases - Drug Profile 226 SP-14019 - Drug Profile 227 SUN-0597 - Drug Profile 228 SWT-01113 - Drug Profile 230 SWT-05141 - Drug Profile 231 Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 232 TA-7906 - Drug Profile 233 tacrolimus - Drug Profile 234 tezepelumab - Drug Profile 235 tofacitinib - Drug Profile 237 tralokinumab - Drug Profile 241 ustekinumab - Drug Profile 243 VTP-38543 - Drug Profile 246 WBI-1001 - Drug Profile 247 WF-10 liposomal - Drug Profile 249 WOL-071007 - Drug Profile 250 XmAb-7195 - Drug Profile 251 YJC-10592 - Drug Profile 252 ZPL-3893787 - Drug Profile 253 ZPL-5212372 - Drug Profile 254 Atopic Dermatitis - Recent Pipeline Updates 255 Atopic Dermatitis - Dormant Projects 311 Atopic Dermatitis - Discontinued Products 320 Atopic Dermatitis - Product Development Milestones 322 Featured News & Press Releases 322 Appendix 331 Methodology 331 Coverage 331 Secondary Research 331 Primary Research 331 Expert Panel Validation 331 Contact Us 331 Disclaimer 332
List of Tables
Number of Products under Development for Atopic Dermatitis, H2 2015 20 Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2015 21 Number of Products under Development by Companies, H2 2015 23 Number of Products under Development by Companies, H2 2015 (Contd..1) 24 Number of Products under Development by Companies, H2 2015 (Contd..2) 25 Number of Products under Development by Companies, H2 2015 (Contd..3) 26 Number of Products under Development by Companies, H2 2015 (Contd..4) 27 Number of Products under Development by Companies, H2 2015 (Contd..5) 28 Number of Products under Investigation by Universities/Institutes, H2 2015 29 Comparative Analysis by Late Stage Development, H2 2015 30 Comparative Analysis by Clinical Stage Development, H2 2015 31 Comparative Analysis by Early Stage Development, H2 2015 32 Comparative Analysis by Unknown Stage Development, H2 2015 33 Products under Development by Companies, H2 2015 34 Products under Development by Companies, H2 2015 (Contd..1) 35 Products under Development by Companies, H2 2015 (Contd..2) 36 Products under Development by Companies, H2 2015 (Contd..3) 37 Products under Development by Companies, H2 2015 (Contd..4) 38 Products under Development by Companies, H2 2015 (Contd..5) 39 Products under Development by Companies, H2 2015 (Contd..6) 40 Products under Investigation by Universities/Institutes, H2 2015 41 Atopic Dermatitis - Pipeline by Abeome Corporation, H2 2015 42 Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2015 43 Atopic Dermatitis - Pipeline by Almirall, S.A., H2 2015 44 Atopic Dermatitis - Pipeline by Amgen Inc., H2 2015 45 Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2015 46 Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 47 Atopic Dermatitis - Pipeline by AnaMar AB, H2 2015 48 Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2015 49 Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2015 50 Atopic Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015 51 Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2015 52 Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2015 53 Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2015 54 Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2015 55 Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2015 56 Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2015 57 Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015 58 Atopic Dermatitis - Pipeline by Creabilis SA, H2 2015 59 Atopic Dermatitis - Pipeline by Delenex Therapeutics AG, H2 2015 60 Atopic Dermatitis - Pipeline by Dermira Inc., H2 2015 61 Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2015 62 Atopic Dermatitis - Pipeline by Eisai Co., Ltd., H2 2015 63 Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 64 Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 65 Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2015 66 Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2015 67 Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 68 Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 69 Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2015 70 Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 71 Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2015 72 Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2015 73 Atopic Dermatitis - Pipeline by IMMD Inc., H2 2015 74 Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2015 75 Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2015 76 Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H2 2015 77 Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2015 78 Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2015 79 Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2015 80 Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2015 81 Atopic Dermatitis - Pipeline by MedImmune, LLC, H2 2015 82 Atopic Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 83 Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2015 84 Atopic Dermatitis - Pipeline by Novartis AG, H2 2015 85 Atopic Dermatitis - Pipeline by Nuvo Research Inc., H2 2015 86 Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 87 Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2015 88 Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2015 89 Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2015 90 Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2015 91 Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015 92 Atopic Dermatitis - Pipeline by R-Tech Ueno, Ltd., H2 2015 93 Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 94 Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2015 95 Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H2 2015 96 Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015 97 Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 98 Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2015 99 Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 100 Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015 101 Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 102 Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2015 103 Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 104 Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015 105 Atopic Dermatitis - Pipeline by Welichem Biotech Inc., H2 2015 106 Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2015 107 Atopic Dermatitis - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015 108 Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2015 109 Assessment by Monotherapy Products, H2 2015 110 Number of Products by Stage and Target, H2 2015 112 Number of Products by Stage and Mechanism of Action, H2 2015 116 Number of Products by Stage and Route of Administration, H2 2015 119 Number of Products by Stage and Molecule Type, H2 2015 121 Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H2 2015 263 Atopic Dermatitis - Dormant Projects, H2 2015 319 Atopic Dermatitis - Dormant Projects (Contd..1), H2 2015 320 Atopic Dermatitis - Dormant Projects (Contd..2), H2 2015 321 Atopic Dermatitis - Dormant Projects (Contd..3), H2 2015 322 Atopic Dermatitis - Dormant Projects (Contd..4), H2 2015 323 Atopic Dermatitis - Dormant Projects (Contd..5), H2 2015 324 Atopic Dermatitis - Dormant Projects (Contd..6), H2 2015 325 Atopic Dermatitis - Dormant Projects (Contd..7), H2 2015 326 Atopic Dermatitis - Dormant Projects (Contd..8), H2 2015 327 Atopic Dermatitis - Discontinued Products, H2 2015 328 Atopic Dermatitis - Discontinued Products (Contd..1), H2 2015 329
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
